Field Efficacy of Topical Nano-Liposomal Amphotericin B (Sina Ampholeish®) Alone or in Combination with Glucantime® and Cryotherapy on Human Cutaneous Leishmaniasis

被引:0
|
作者
Alizadeh, Zahra [1 ]
Shirzadi, Mohammad Reza [2 ]
Hassanpour, Gholam Reza [3 ]
Keshavarz, Hossein [1 ,3 ]
Mohebali, Fatemeh [4 ]
Eskandari, Seyed Ebrahim [5 ]
Zeinali, Mohammad [2 ]
Shirmohammad, Sedigheh [3 ]
Mohebali, Mehdi [1 ,3 ]
机构
[1] Univ Tehran Med Sci, Sch Publ Hlth, Dept Med Parasitol & Mycol, Tehran, Iran
[2] Minist Hlth & Med Educ, Ctr Communicable Dis Control, Zoonoses Control Dept, Tehran, Iran
[3] Univ Tehran Med Sci, Ctr Res Endem Parasites Iran, Tehran, Iran
[4] Mat & Energy Res Ctr MERC, Karaj, Iran
[5] Univ Tehran Med Sci, Ctr Res & Training Skin Dis & Leprosy, Tehran, Iran
关键词
Cutaneous leishmaniasis; Treatment; SinaAmpholeish (R); Glucantime (R); Cryotherapy; Human; Iran; FORMULATION; SAFETY;
D O I
暂无
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Background: Cutaneous leishmaniasis (CL) is a parasitic disease that presents a broad spectrum of clinical features. Treatment of CL is problematic. We aimed to compare the field therapeutic efficacy of topical nanoliposomes containing 0.4% amphotericin B (Nano Lip-AmB) alone and in combination with cryotherapy and/or Glucantime (R) on human CL in the endemic areas of Iran.Methods: This retrospective study was performed based on the results of using Nano Lip-AmB alone or with Glucantime (R) and/or cryotherapy in the treatment of zoonotic cutaneous leishmaniasis (ZCL) in patients referred to health centers of Isfahan, Golestan and Ilam Provinces of Iran as endemic foci of ZCL caused by Leishmania major besides Mashhad and Bam cities as endemic foci of anthroponotic cutaneous leishmaniasis (ACL) caused by with L. tropica.Results: Two hundred and seventy-eight patients with CL were included in the current study. All of the patients (100%) who received Nano Lip-AmB alone or in combination with Glucantime (R) and/or cryotherapy based on guideline of Iranian national committee for the treatment of CL. Two patients with 7 skin lesions, who was resident in ACL endemic area and received Nano Lip-AmB plus Glucantime (R) and an-other patient was a resident of ZCL endemic area and received Nano Lip-AmB plus cryotherapy showed clinical relapses after treatment.Conclusion: Sina Ampholeish (R) in combination with other standard protocols of treatment of CL is well tolerated and with acceptable clinical efficacy rate.
引用
收藏
页码:419 / 426
页数:8
相关论文
共 14 条
  • [11] Combination therapy with liposomal amphotericin b (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case
    Ferreira Gomes, Maria Antonia
    Cantidio de Medeiros, Lana Lira
    Dantas Lobo, Fernanda Paula
    Silva Wanderley, Nathalia Rayane
    Rodrigues Matos, Ana Paula
    Jacome, Tacito do Nascimento
    Lins Monteiro, Maria Goretti
    Luz, Kleber Giovanni
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2018, 51 (03) : 393 - 396
  • [12] Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B
    Wijnant, Gert-Jan
    Van Bocxlaer, Katrien
    Francisco, Amanda Fortes
    Yardley, Vanessa
    Harris, Andy
    Alavijeh, Mo
    Murdan, Sudaxshina
    Croft, Simon L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (10)
  • [13] Evaluation of the Efficacy of Amphotericin B and Terbinafine Microemulsions and Their Combination on Cutaneous Leishmaniasis and Comparison with the Conventional Drug Form in BALB/c Mice
    Baharvandi, Zeynab
    Salimi, Anayatollah
    Arjmand, Reza
    Jelowdar, Ali
    Rafiei, Abdollah
    AAPS PHARMSCITECH, 2022, 23 (07)
  • [14] Evaluation of the Efficacy of Amphotericin B and Terbinafine Microemulsions and Their Combination on Cutaneous Leishmaniasis and Comparison with the Conventional Drug Form in BALB/c Mice
    Zeynab Baharvandi
    Anayatollah Salimi
    Reza Arjmand
    Ali Jelowdar
    Abdollah Rafiei
    AAPS PharmSciTech, 23